Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-amylase is a calcium-dependent enzyme that catalyzes the endohydrolysis of internal α-(1→4) glycosidic bonds in starches and related polysaccharides, producing smaller sugars like maltose and dextrins. It is widely distributed across animals (notably humans), plants, fungi, and bacteria. In humans, two main forms exist—salivary alpha-amylase initiates starch digestion in the mouth while pancreatic alpha-amylase continues this process in the small intestine. Structurally, it features a characteristic three-domain architecture with an eight-stranded α/β barrel catalytic domain containing key acidic residues at its active site; calcium ions stabilize its structure. Alpha-amylases are essential for energy metabolism from complex carbohydrates and have major industrial applications including food processing and biotechnology. Clinically relevant inhibitors are used to manage type 2 diabetes by slowing carbohydrate absorption from food.
Drugs such as acarbose inhibit alpha-amylase by binding to its active site, thereby blocking the hydrolysis of dietary starch into absorbable sugars and reducing postprandial blood glucose spikes.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-amylase (α-Amylase).